# Effectiveness of Disinfectants Against Candida auris and Other Candida Species

Jennifer L. Cadnum, BS;<sup>1</sup> Aaron A. Shaikh, BS;<sup>2</sup> Christina T. Piedrahita, BS;<sup>1</sup> Thriveen Sankar, MBA;<sup>1</sup> Annette L. Jencson, CIC;<sup>1</sup> Emily L. Larkin, BS;<sup>3,4</sup> Mahmoud A. Ghannoum, PhD;<sup>3,4</sup> Curtis J. Donskey, MD<sup>2,5</sup>

Contaminated surfaces are a suspected source for dissemination of the globally emerging pathogen *Candida auris*. In laboratory testing, sporicidal and improved hydrogen peroxide disinfectants were highly effective against *C. auris*, *C. glabrata*, and *C. albicans*. The widely used quaternary ammonium disinfectants exhibited relatively poor activity against all of the *Candida* species.

Infect Control Hosp Epidemiol 2017;38:1240-1243

Candida auris is a globally emerging pathogen that is often resistant to multiple antifungal agents.<sup>1–3</sup> In several reports, *C. auris* has been recovered from the hospital environment, suggesting that contaminated surfaces may be a source of transmission.<sup>1,2</sup> The Centers for Disease Control and Prevention (CDC) has therefore recommended daily and postdischarge disinfection of surfaces in rooms of patients with *C. auris* infection.<sup>4</sup> Moreover, the use of an Environmental Protection Agency (EPA)–registered, hospital-grade disinfectant effective against *Clostridium difficile* spores was specified.<sup>4</sup> However, nonsporicidal disinfectants are widely used and many have an EPA-registered antifungal claim.<sup>5</sup> No hospital disinfectants are registered for use specifically against *C. auris*, and it is not known whether *C. auris* is less susceptible to disinfectants than other *Candida* species.

## METHODS

We evaluated the efficacy of 9 commercial disinfectants and the common household disinfectant white distilled vinegar (>5% acetic acid, pH 2.0) against *C. auris, C. albicans*, and *C. glabrata*. For comparison, 3 strains of methicillin-resistant *Staphylococcus aureus* (MRSA) were tested. The 5 *C. auris* strains have been described previously<sup>3,6</sup>; the strains included 3 multidrug-resistant clinical isolates (MRL#31102 and #31103 and CBS#12373) and 2 drug-susceptible isolates (CBS#10913 and CDC strain AR-BANK#0381). The 4 *C. albicans* strains included American Type Culture Collection (ATCC) strains SC#5314 and #10231 and 2 clinical strains from the Center for Medical Mycology, Cleveland, Ohio (MRL#32249 and #32708). The *C. glabrata* clinical strains were MRL#31820, #34870, and #9547. The 3 MRSA strains included ATCC strain 43,300 and 2 clinical isolates.

The disinfectants and their contact times are shown in Table 1. For the commercial products, the contact times were based on the manufacturer's recommendations except for Clorox Healthcare hydrogen peroxide cleaner disinfectant (ie, a 1-minute exposure was used rather than the 3 minutes recommended for C. albicans based on preliminary experiments that demonstrated excellent activity with the shorter exposure time). Testing of disinfectant efficacy was conducted according to the American Society for Testing and Materials (ASTM) Standard quantitative carrier disk test method (ASTM E2197-11).<sup>7</sup> To simulate the presence of organic material, 5% fetal calf serum (Remel, Lenexa, KS) was added to the inoculum. The steel-disk carriers were inoculated with ~10<sup>6</sup> colonyforming units (CFUs) of washed Candida species or MRSA from an overnight culture; the test was not considered valid unless a minimum of 10<sup>5</sup> CFU was recovered from control carriers. After disinfectant exposure, carriers were neutralized with Dey-Engley neutralizer (Remel), except for Oxivir Tb (Diversey, Charlotte, NC) and Clorox Healthcare hydrogen peroxide cleaner disinfectant (Clorox, Oakland, CA), which were neutralized with 0.1% Tween 80 and 3% glycine in 0.85% NaCl. Serial dilutions were plated onto Sabouraud dextrose agar (Becton-Dickinson, Sparks, MD) and incubated at 37°C for 72 hours. Log reductions were calculated by subtracting viable organisms recovered after disinfectant exposure versus deionized water controls. Experiments were performed in triplicate.

To determine whether different test methods might yield different results for a quaternary ammonium compound, we compared reductions of the Candida species and MRSA for Virex II 256 using ASTM E-2197-11 and the AOAC (Association of Official Agricultural Chemists) Official Method 961.02 for Germicidal Spray Products.<sup>8</sup> For this comparison, we included tests with a lower inoculum resulting in 10<sup>4</sup> CFU recovered from control carriers. The rationale for testing the reduced inoculum was that the EPA product performance test guideline OCSPP 810.2200 for disinfectants with fungicidal claims recommends that carriers have a concentration of 10<sup>4</sup> to 10<sup>5</sup> CFU per carrier.<sup>9</sup> In the AOAC method, glass microscope slides are used as carriers and the inoculum is spread to cover approximately 1 square inch. For all experiments, log reductions were compared for different disinfectants using linear modeling with post hoc Tukey's adjustment for multiple comparisons. Data were analyzed using SPSS statistical software version 10.0 (SPSS, Chicago, IL).

## RESULTS

Figure 1 shows the mean reductions for the disinfectants using the ASTM method. For MRSA, each of the disinfectants reduced recovery by ~6  $\log_{10}$  CFU. The data for each of the *Candida* species was pooled because there were no significant

Disinfectant	Active Components	Contact Time <sup>a</sup>	Sporicidal Claim <sup>b</sup>	<i>Candida albicans</i> Claim <sup>c</sup>
Clorox Healthcare bleach germicidal cleaner	Sodium hypochlorite 0.65%	1 min	Yes	Yes
Clorox Healthcare Fuzion cleaner disinfectant	Sodium hypochlorite 0.39%	1 min	Yes	Yes
Clorox germicidal bleach (1:10 dilution)	Sodium hypochlorite 0.825% when diluted	1 min	Yes	Yes
OxyCide daily disinfectant	Peracetic acid 1200 parts per million, hydrogen peroxide <1%, acetic acid	3 min	Yes	Yes
Clorox Healthcare hydrogen peroxide cleaner disinfectant	Hydrogen peroxide 1.4%	1 min <sup>d</sup>	No	Yes
Oxivir Tb	Hydrogen peroxide 0.5%	10 min	No	Yes
White distilled vinegar	Acetic acid >5% (pH 2.0)	3 min <sup>e</sup>	No	No
Purell healthcare surface disinfectant	Ethyl alcohol 29.4%	30 s	No	Yes
Lysol all-purpose cleaner	Alkyl dimethyl benzyl ammonium chlorides	10 min	No	Yes
Virex II 256	Didecyl dimethyl ammonium chloride, n-Alkyl dimethyl benzyl ammonium chloride	10 min	No	Yes

#### TABLE 1. Characteristics of the Disinfectants Tested

<sup>a</sup>Contact time for disinfectants based on manufacturers' recommendations for *Candida albicans* unless otherwise specified.

<sup>b</sup>Environmental Protection Agency-registered claim against *Clostridium difficile* spores.

<sup>c</sup>Environmental Protection Agency-registered claim against Candida albicans.

<sup>d</sup>A 1-minute exposure was used, but the claim is based on a 3-minute exposure.

<sup>e</sup>There is no established contact time for vinegar.




FIGURE 1. Mean log reductions for each of the disinfectants against the 3 *Candida* species and MRSA using the American Society for Testing and Materials (ASTM) Standard Quantitative Carrier Disk Test Method (ASTM E-2197-02).<sup>7</sup> Log reductions were calculated by subtracting viable organisms recovered after exposure to the disinfectants versus deionized water controls. Vinegar, Purell Healthcare Surface Disinfectant, and the 2 quaternary ammonium disinfectants were significantly less effective against the *Candida* species than against MRSA ( $P \le .02$ ). Error bars show standard error. MRSA, methicillin-resistant *Staphylococcus aureus*.

differences in reductions for different strains. The 3 bleach disinfectants, OxyCide, Clorox Healthcare hydrogen peroxide cleaner disinfectant, and Oxivir TB consistently reduced the *Candida* species by  $\geq 5 \log_{10}$  CFU, and there were no significant differences in reductions for the *Candida* species and MRSA (P > .05). Vinegar, Purell Healthcare surface disinfectant (Gojo, Akron, OH), and the 2 quaternary ammonium disinfectants were significantly less effective against *Candida* species than against MRSA ( $P \leq .02$ ). There were no significant differences in efficacy against *C. auris* versus the other *Candida* species.

Compared to the ASTM method, the AOAC method resulted in significantly greater measured log reductions (mean ± SE) for Virex II 256 against *C. albicans* ( $3.3 \pm 0.4$  versus  $0.5 \pm 0.4$ ), *C. glabrata* ( $3.8 \pm 0.4$  vs  $0.4 \pm 0.2$ ), and *C. auris* ( $2.2 \pm .2$  vs  $0.7 \pm 0.3$ ) (P < .05 for each comparison), but not MRSA (ie, ~6 log<sub>10</sub>CFU reductions with both methods), when the inoculum was  $10^6$  CFUs per carrier (P < .05 for each comparison).

For the ASTM E2197-11 method, reducing the inoculum such that  $10^4$  CFUs were recovered from the control carriers significantly enhanced the measured reduction in *Candida* species achieved by Virex II 256 (~3 vs 0.5 to 2 log reduction; P < .01). For the AOAC method, a similar reduction in the inoculum resulted in 4 log reductions in each of the *Candida* species (data not shown).

## DISCUSSION

Many disinfectants have an EPA-registered fungal claim based on efficacy against *C. albicans* or *Trichophyton mentagrophytes*.<sup>5</sup> However, interim recommendations from the CDC have specified that an EPA-registered hospital-grade disinfectant effective against *C. difficile* spores be used for *C. auris*.<sup>4</sup> Our results provide support for that recommendation but also demonstrate that nonsporicidal improved hydrogen peroxide disinfectants are highly active against *Candida* species, including *C. auris*. There was no evidence that *C. auris* has greater resistance to disinfectants than do other *Candida* species.

The relatively poor activity of the quaternary ammonium disinfectants against all *Candida* species is concerning because these agents are widely used. In contrast to MRSA, we found that differences in test methods may markedly impact the measured efficacy of quaternary ammonium disinfectants against *Candida* species. Our results suggest that factors such as use of a smaller organism inoculum and spreading of the inoculum may enhance the measured reductions. In that regard, it should be noted that the EPA has recently released interim guidance for testing the efficacy of liquid antimicrobials against *C. auris*<sup>6</sup>; the recommended methods are similar to the ASTM method used in our study, and both methods yield similar results (unpublished data).

It is possible that the environment may be an underappreciated reservoir for the spread of *Candida* species other than *C. auris*. In a recent study, we demonstrated that *C. auris* and other *Candida* species have a similar propensity to survive on surfaces, and *Candida* species were frequently recovered from the hospital environment, particularly from moist surfaces.<sup>10</sup> Moreover, previous studies have implicated the environment as a potential source for transmission of *Candida* species.<sup>11</sup>

Our study has some limitations. We studied only 2 quaternary ammonium disinfectants and cannot exclude the possibility that other quaternary ammonium compounds may have greater activity. We did not assess the efficacy of the disinfectants on hospital surfaces. It is possible that quaternary ammonium compounds may exhibit greater efficacy on real-world surfaces if smaller numbers of *Candida* species are present.

## ACKNOWLEDGMENTS

*Financial support:* This work was funded by a Merit Review grant (grant no. BX002944-01A1) from the Department of Veterans Affairs to C.J.D.

*Potential conflicts of interest*: C.J.D. has received research grants from Merck, GOJO, Altapure, EcoLab, and Clorox and serves on advisory boards for 3M and Synthetic Biologics. All other authors report no conflicts of interest relevant to this article.

Affiliations: 1. Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio; 2. Case Western Reserve University School of Medicine, Cleveland, Ohio; 3. Center for Medical Mycology, Case Western Reserve University, Cleveland, Ohio; 4. University Hospitals Cleveland Medical Center, Cleveland, Ohio; 5. Geriatric Research, Education, and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio

Address correspondence to Curtis J. Donskey, MD, Geriatric Research, Education, and Clinical Center 1110W, Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106 (Curtis.Donskey@va.gov).

Received May 8, 2017; accepted July 5, 2017; electronically published August 10, 2017

© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2017/3810-0015. DOI: 10.1017/ice.2017.162

### REFERENCES

- Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of *Candida auris*, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013– August 2016. *Am J Transplant* 2017;17:296–299.
- Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control* 2016;5:35.
- 3. Larkin E, Hager C, Chandra J, et al. The emerging *Candida auris*: characterization of growth phenotype, virulence factors, antifungal activity, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. *Antimicrob Agents Chemother* 2017;Feb 21. pii: AAC 02396–16.
- Fungal diseases: Candida auris. Centers for Disease Control and Preventions website. https://www.cdc.gov/fungal/diseases/ candidiasis/candida-auris.html. Updated 2017. Accessed July 10, 2017.
- List K: EPA's registered antimicrobial products effective against *Clostridium difficile* spores. US Environmental Protection Agency website. https://www.epa.gov/sites/production/files/2017-01/documents/20172701.listk\_.pdf. Published 2017. Accessed July 10, 2017.

- 6. EPA MLB SOP MB-35-00: OECD Quantitative method for evaluating the efficacy of liquid antimicrobials against *Candida auris* on hard, non-porous surfaces. US Environmental Protection Agency Office of Pesticide Programs website. https://www.epa. gov/pesticide-registration/interim-guidance-efficacy-evaluationproducts-claims-against-candida-auris-0. Published 2017. Accessed July 10, 2017.
- ASTM International, Designation E2197: standard quantitative disk carrier test method for determining bactericidal, virucidal, fungicidal, mycobactericidal, and sporicidal activities of chemicals, 2011.
- AOAC Official Method 961.02 Germicidal spray products as disinfectants. Microchem Laboratory website. http://microchemlab. com/test/aoac-germicidal-spray-products-test-aoac-96102. Published 2015. Accessed July 10, 2017.
- Environmental Protection Agency. Product performance test guidelines OCSPP 810.2200: disinfectants for use on hard surfaces—efficacy data recommendations. US Federal Regulations website. https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0150-0021. Published 2012. Accessed July 10, 2017.
- Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of *Candida auris* and other *Candida* species. *Infect Control Hosp Epidemiol* 2017;1–3. doi: 10.1017/ice.2017.127 [Epub July 11, 2017].
- 11. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. *Clin Infect Dis* 1996;22(Suppl 2): S89–S94.